Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
Type:
Grant
Filed:
January 27, 2009
Date of Patent:
January 17, 2012
Assignee:
Galapagos BV
Inventors:
Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen
Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.
Type:
Application
Filed:
February 1, 2011
Publication date:
May 19, 2011
Applicant:
GALAPAGOS BV
Inventors:
Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme
Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a subject.
Type:
Application
Filed:
October 7, 2009
Publication date:
April 8, 2010
Applicant:
Galapagos BV
Inventors:
Nick Vandeghinste, Peter Herwig Maria Tomme, Frits Michiels, Libin Ma, Blandine Mille-Baker, Helmuth H.G. van Es
Abstract: The application discloses methods for identifying and using compounds that inhibit extra-cellular matrix (ECM) degradation and inflammation, using a polypeptide sequence including SEQ ID NO: 17-127 (hereinafter “TARGETS”) and fragments thereof, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), comprising a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a polypeptide of SEQ ID NO: 17-127, useful in pharmaceutical compositions comprising said agent, for the treatment, or prevention, of chronic joint degenerative and/or inflammatory diseases such as rheumatoid arthritis.
Type:
Grant
Filed:
October 14, 2005
Date of Patent:
February 3, 2009
Assignee:
Galapagos BV
Inventors:
Reginald Brys, Nick Vandeghinste, Peter Herwig Maria Tomme, Hubertus Johanus Matheus Klaassen